biostudies-literatureUnknown52Kalfon P<h4>Background</h4>Severe hypoxemia in patients with COVID-19 pneumonia might result from hypoxic pulmonary vasoconstriction, contributing to ventilation/perfusion (V/Q) mismatch. Because almitrine improves V/Q, it might reduce the risk for mechanical ventilation (MV) in such patients. Our primary objective was to determine the effect of almitrine on the need for MV at day 7.<h4>Methods</h4>In a randomised double-blind placebo-controlled trial involving 15 ICUs, patients hospitalized for COVID-19 pneumonia and experiencing acute hypoxemic respiratory failure were randomly assigned to receive 5 days of intravenous low-dose (2 µg.kg^-1.min^-1) almitrine or placebo. The primary outcome was endotracheal intubation for MV or death within 7 days after randomisation. SecondaryEClinicalMedicine101663https://www.ebi.ac.uk/biostudies/studies/S-EPMC9489996biostudies-literatureEffect of intravenous almitrine on intubation or mortality in patients with COVID-19 acute hypoxemic respiratory failure: A multicentre, randomised, double-blind, placebo-controlled trial.PMC9489996Rousseau AChousterman BDepret FSimon TKalfon PTibi AWeiss ERiou BAudibert JConstantin JMRemerand FPayen JFFreund YCachanado MfalseEffect of intravenous almitrine on intubation or mortality in patients with COVID-19 acute hypoxemic respiratory failure: A multicentre, randomised, double-blind, placebo-controlled trial.<h4>Background</h4>Severe hypoxemia in patients with COVID-19 pneumonia might result from hypoxic pulmonary vasoconstriction, contributing to ventilation/perfusion (V/Q) mismatch. Because almitrine improves V/Q, it might reduce the risk for mechanical ventilation (MV) in such patients. Our primary objective was to determine the effect of almitrine on the need for MV at day 7.<h4>Methods</h4>In a randomised double-blind placebo-controlled trial involving 15 ICUs, patients hospitalized for COVID-19 pneumonia and experiencing acute hypoxemic respiratory failure were randomly assigned to receive 5 days of intravenous low-dose (2 µg.kg^-1.min^-1) almitrine or placebo. The primary outcome was endotracheal intubation for MV or death within 7 days after randomisation. Secondary2022-01-01T00:00:00Z2022 Oct2026-05-27T18:55:29.101Z2025-04-19T09:53:52.407ZS-EPMC94899963615789510.1016/j.eclinm.2022.101663